retatrutide phase 3 triumph Shows 28.3% Weight Loss in Obesity Trial retatrutide #obesity #osteoarthritis #clinicaltrials #medicine

GLP-1 FAQ Who is eligible for these medications

Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

Clinical Evidence Semaglutide: proof of concept for high-efficacy GLP-1 therapy Semaglutide 2.4 mg established that selective GLP-1 receptor agonism could produce substantial weight loss in adults with obesity

doi:10.1016/j.phymed.2019.153099 Roozbeh N, Ghazanfarpour M, Khadivzadeh T, Kargarfard L, Dizavandi FR, Shariati K

Journals assumed that somehow they would know to avoid retracted papers. However, retractions seldom received as much attention as the original headline-grabbing studies